Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 6/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FABP1 | P07148 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979385 | 0.93 | MAPT (0.40) | BCL9CTNNB1MAPTSIRT2F10 | |
| SCHEMBL4267800 | 0.92 | LMNA (0.48) | LMNASMN1; SMN2FABP1 | |
| SCHEMBL3974845 | 0.91 | LMNA (0.49) | LMNASMN1; SMN2 | |
| SCHEMBL14215452 | 0.90 | F10 (0.41) | BCL9CTNNB1SIRT2F10LMNA | |
| SCHEMBL4084588 | 0.90 | CYP1A2 (0.45) | MAPTSIRT2LMNASMN1; SMN2FABP1 | |
| SCHEMBL4080746 | 0.90 | SIRT2 (0.41) | MAPTSIRT2LMNAEPHX2FABP1 | |
| SCHEMBL3984312 | 0.89 | KIF11 (0.46) | MAPTSIRT2F10LMNAEPHX2 | |
| SCHEMBL4980199 | 0.89 | C5AR1 (0.45) | MAPTLMNASMN1; SMN2 | |
| SCHEMBL3980256 | 0.89 | LMNA (0.49) | LMNASMN1; SMN2 | |
| SCHEMBL3973689 | 0.86 | KMT2A (0.48) | MAPTSIRT2EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056810-A2 | THIOUREA COMPOUNDS | National Health Research Institutes (TW) | 2009-05-13 | — | — | EP | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| WO-2008022204-A2 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096875-A1 | THIOUREA COMPOUNDS | TPMT, HAVCR2, ETV6 | BCL9 436/4885CTNNB1 3832/4885MAPT 3656/4885 |
| US-20080113975-A1 | THIOUREA COMPOUNDS | TPMT, HAVCR2, EIF2AK2 | BCL9 517/4885CTNNB1 3848/4885MAPT 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.